ArticleJournal of biomedical optics2011
Detection of enzyme activity in orthotopic murine breast cancer by fluorescence lifetime imaging using a fluorescence resonance energy transfer-based molecular probe.
Article in Journal of biomedical optics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Near-infrared probes for luminescence lifetime imaging.Nanotheranostics · 2022Review
- Fluorescence lifetime imaging microscopy: fundamentals and advances in instrumentation, analysis, and applications.Journal of biomedical optics · 2020Review
- Recent progress in the imaging detection of enzyme activitiesRSC advances · 2019Review
- Fluorescence lifetime-based contrast enhancement of indocyanine green-labeled tumors.Journal of biomedical optics · 2017Article
- Enhancing in vivo tumor boundary delineation with structured illumination fluorescence molecular imaging and spatial gradient mapping.Journal of biomedical optics · 2016Article
- Molecular probes for fluorescence lifetime imaging.Bioconjugate chemistry · 2015Review
- MMP-2/9-Specific Activatable Lifetime Imaging Agent.Sensors (Basel, Switzerland) · 2015Article
- Visualization of pulmonary clearance mechanisms via noninvasive optical imaging validated by near-infrared flow cytometry.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2015Article
- Dual-radiolabeled nanoparticle SPECT probes for bioimaging.Nanoscale · 2015Article
- Synthesis of nitric oxide probes with fluorescence lifetime sensitivity.Organic & biomolecular chemistry · 2013Article
- Dynamic optical projection of acquired luminescence for aiding oncologic surgery.Journal of biomedical optics · 2013Article
- Enzyme-activatable imaging probe reveals enhanced neutrophil elastase activity in tumors following photodynamic therapy.Journal of biomedical optics · 2013Article
- BLOOD TRIGGERED RAPID RELEASE POROUS NANOCAPSULES.RSC advances · 2013Article
- In vivo fluorescence lifetime detection of an activatable probe in infarcted myocardium.Journal of biomedical optics · 2012Article
- New frontier in hypericin-mediated diagnosis of cancer with current optical technologies.Annals of biomedical engineering · 2012Review
- FLIM-FRET for Cancer Applications.Current molecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Cancer-related enzyme activity can be detected noninvasively using activatable fluorescent molecular probes. In contrast to "always-on" fluorescent molecular probes, activatable probes are relatively nonfluorescent at the time of administration due to intramolecular fluorescence resonance energy transfer (FRET). Enzyme-mediated hydrolysis of peptide linkers results in reduced FRET and increase of fluorescence yield. Separation of signal from active and inactive probe can be difficult with conventional intensity-based fluorescence imaging. Fluorescence lifetime (FLT) measurement is an alternative method to detect changes in FRET. Thus, we investigate FLT imaging for in vivo detection of FRET-based molecular probe activation in an orthotopic breast cancer model. Indeed, the measured FLT of the enzyme-activatable molecular probe increases from 0.62 ns just after injection to 0.78 ns in tumor tissue after 4 h. A significant increase in FLT is not observed for an always-on targeted molecular probe with the same fluorescent reporter. These results show that FLT contrast is a powerful addition to preclinical imaging because it can report molecular activity in vivo due to changes in FRET. Fluorescence lifetime imaging exploits unique characteristics of fluorescent molecular probes that can be further translated into clinical applications, including noninvasive detection of cancer-related enzyme activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.